Construction and functional analysis of a bispecific antibody that targets TNF-α and ED-B.
- Author:
Lu-Jun LI
;
Yan-Qun YANG
;
Xue-Ping HU
;
Mian XIE
;
Meng-Yuan LIU
- Publication Type:Journal Article
- MeSH:
Animals;
Antibodies, Bispecific;
chemistry;
Antibodies, Monoclonal;
chemistry;
Arthritis, Experimental;
Escherichia coli;
Fibronectins;
chemistry;
Half-Life;
Humans;
Mice;
Single-Chain Antibodies;
chemistry;
Tumor Necrosis Factor-alpha;
chemistry
- From:
Acta Pharmaceutica Sinica
2014;49(12):1665-1673
- CountryChina
- Language:Chinese
-
Abstract:
In order to enhance the specificity of TNF-α monoclonal antibody to inflamed site, a bispecific antibody BsDb that targets TNF-α and the extra-domain B (ED-B) of fibronectin (FN) was constructed by covalently linking the anti-TNF-α single chain Fv antibody (TNF-scFv) and the anti-ED-B scFv L19 via a flexible peptide linker deriving from human serum albumin (HSA). ED-B is an antigen specifically expressed at the inflamed site. BsDb is expressed in E. coli, identified by immunoblot, and purified with affinity chromatography. This was followed by further examination of its bioactivities and pharmacokinetics. We demonstrated that BsDb retained the immunoreactivity of its original antibodies as it could simultaneously bind to TNF-α and ED-B and neutralize the biological action of TNF-α. In the collagen-induced arthritis mice model, BsDb selectively accumulate in the inflamed joint with a maximal uptake of (12.2 ± 1.50)% ID/g in a single inflamed paw and retain in the inflamed paw for at least 72 h. In contrast, BsDb showed a short serum half-life of (0.50 ± 0.05) h and a rapid clearance from normal tissues. The findings reported herein indicate that BsDb has good specificity to the inflamed site and low toxicity to normal tissues. BsDb is therefore likely to have greater clinical applications in the treatment of rheumatoid arthritis and other autoimmune diseases. This laid a stable basis for its preclinical study.
